Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Dynamic modification of sphingomyelin in lipid microdomains controls development of obesity, fatty liver, and type 2 diabetes.

Mitsutake S, Zama K, Yokota H, Yoshida T, Tanaka M, Mitsui M, Ikawa M, Okabe M, Tanaka Y, Yamashita T, Takemoto H, Okazaki T, Watanabe K, Igarashi Y.

J Biol Chem. 2011 Aug 12;286(32):28544-55. doi: 10.1074/jbc.M111.255646. Epub 2011 Jun 13.

2.

Precursor cells in mouse islets generate new beta-cells in vivo during aging and after islet injury.

Liu H, Guz Y, Kedees MH, Winkler J, Teitelman G.

Endocrinology. 2010 Feb;151(2):520-8. doi: 10.1210/en.2009-0992. Epub 2010 Jan 7.

3.

Link between plasma ceramides, inflammation and insulin resistance: association with serum IL-6 concentration in patients with coronary heart disease.

de Mello VD, Lankinen M, Schwab U, Kolehmainen M, Lehto S, Seppänen-Laakso T, Oresic M, Pulkkinen L, Uusitupa M, Erkkilä AT.

Diabetologia. 2009 Dec;52(12):2612-5. doi: 10.1007/s00125-009-1482-9. Epub 2009 Aug 11.

PMID:
19669729
4.

Macrophage sphingomyelin synthase 2 deficiency decreases atherosclerosis in mice.

Liu J, Huan C, Chakraborty M, Zhang H, Lu D, Kuo MS, Cao G, Jiang XC.

Circ Res. 2009 Jul 31;105(3):295-303. doi: 10.1161/CIRCRESAHA.109.194613. Epub 2009 Jul 9.

5.

A new acridone alkaloid from Micromelum integerrimum.

Yang XL, Xie ZH, Jiang XJ, Huang YB, Liu JK.

Chem Pharm Bull (Tokyo). 2009 Jul;57(7):734-5.

6.

Sphingomyelin synthase-related protein SMSr controls ceramide homeostasis in the ER.

Vacaru AM, Tafesse FG, Ternes P, Kondylis V, Hermansson M, Brouwers JF, Somerharju P, Rabouille C, Holthuis JC.

J Cell Biol. 2009 Jun 15;185(6):1013-27. doi: 10.1083/jcb.200903152. Epub 2009 Jun 8.

7.

Identification of small subunits of mammalian serine palmitoyltransferase that confer distinct acyl-CoA substrate specificities.

Han G, Gupta SD, Gable K, Niranjanakumari S, Moitra P, Eichler F, Brown RH Jr, Harmon JM, Dunn TM.

Proc Natl Acad Sci U S A. 2009 May 19;106(20):8186-91. doi: 10.1073/pnas.0811269106. Epub 2009 May 5. Erratum in: Proc Natl Acad Sci U S A. 2009 Jun 16;106(24):9931.

8.

Glycosphingolipids and insulin resistance.

Langeveld M, Aerts JM.

Prog Lipid Res. 2009 May-Jul;48(3-4):196-205. doi: 10.1016/j.plipres.2009.03.002. Epub 2009 Mar 20. Review.

PMID:
19303901
9.

Co-firing of oil sludge with coal-water slurry in an industrial internal circulating fluidized bed boiler.

Liu J, Jiang X, Zhou L, Wang H, Han X.

J Hazard Mater. 2009 Aug 15;167(1-3):817-23. doi: 10.1016/j.jhazmat.2009.01.061. Epub 2009 Jan 24.

PMID:
19249155
10.

Sphingomyelin synthase 2 deficiency attenuates NFkappaB activation.

Hailemariam TK, Huan C, Liu J, Li Z, Roman C, Kalbfeisch M, Bui HH, Peake DA, Kuo MS, Cao G, Wadgaonkar R, Jiang XC.

Arterioscler Thromb Vasc Biol. 2008 Aug;28(8):1519-26. doi: 10.1161/ATVBAHA.108.168682. Epub 2008 Jun 19.

11.

Human skeletal muscle ceramide content is not a major factor in muscle insulin sensitivity.

Skovbro M, Baranowski M, Skov-Jensen C, Flint A, Dela F, Gorski J, Helge JW.

Diabetologia. 2008 Jul;51(7):1253-60. doi: 10.1007/s00125-008-1014-z. Epub 2008 May 6.

PMID:
18458871
12.

Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism.

Holland WL, Summers SA.

Endocr Rev. 2008 Jun;29(4):381-402. doi: 10.1210/er.2007-0025. Epub 2008 May 1. Review.

13.
14.

Dissociation of the insulin receptor and caveolin-1 complex by ganglioside GM3 in the state of insulin resistance.

Kabayama K, Sato T, Saito K, Loberto N, Prinetti A, Sonnino S, Kinjo M, Igarashi Y, Inokuchi J.

Proc Natl Acad Sci U S A. 2007 Aug 21;104(34):13678-83. Epub 2007 Aug 15.

15.

Inhibition of sphingomyelin synthase (SMS) affects intracellular sphingomyelin accumulation and plasma membrane lipid organization.

Li Z, Hailemariam TK, Zhou H, Li Y, Duckworth DC, Peake DA, Zhang Y, Kuo MS, Cao G, Jiang XC.

Biochim Biophys Acta. 2007 Sep;1771(9):1186-94. Epub 2007 Jun 6.

16.

Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes.

Zhao H, Przybylska M, Wu IH, Zhang J, Siegel C, Komarnitsky S, Yew NS, Cheng SH.

Diabetes. 2007 May;56(5):1210-8.

17.

Disordered lipid metabolism and the pathogenesis of insulin resistance.

Savage DB, Petersen KF, Shulman GI.

Physiol Rev. 2007 Apr;87(2):507-20. Review.

18.

Enhanced apoA-I-dependent cholesterol efflux by ABCA1 from sphingomyelin-deficient Chinese hamster ovary cells.

Nagao K, Takahashi K, Hanada K, Kioka N, Matsuo M, Ueda K.

J Biol Chem. 2007 May 18;282(20):14868-74. Epub 2007 Apr 3.

19.

Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance.

Holland WL, Brozinick JT, Wang LP, Hawkins ED, Sargent KM, Liu Y, Narra K, Hoehn KL, Knotts TA, Siesky A, Nelson DH, Karathanasis SK, Fontenot GK, Birnbaum MJ, Summers SA.

Cell Metab. 2007 Mar;5(3):167-79.

20.

Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity.

Aerts JM, Ottenhoff R, Powlson AS, Grefhorst A, van Eijk M, Dubbelhuis PF, Aten J, Kuipers F, Serlie MJ, Wennekes T, Sethi JK, O'Rahilly S, Overkleeft HS.

Diabetes. 2007 May;56(5):1341-9. Epub 2007 Feb 7.

Supplemental Content

Support Center